MaxCyte Inc (MXCT) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of MaxCyte Inc $0.82, price $1.19, upside -31.1%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch MaxCyte Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.6760 – $17.20 · fair‑value band $0.5400 – $1.02 · the $1.19 price screens above the $0.8200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow MaxCyte in your weekly email
Every Wednesday you see whether MaxCyte is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Show more
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Stock analysis
MaxCyte Inc (MXCT) currently trades at $1.19, while our model-based Fair Value estimate is $0.8200, implying the stock looks roughly 45.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.5400 (bear) to $1.02 (bull), the price of $1.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
MaxCyte Inc reported revenue of $33.0M in FY2025 versus $33.9M in FY2021, a compound −0.6%/yr. Reported net income was −$44.6M in FY2025.
Key figures
Market cap $127M · P/S ratio 4.01 · EPS (TTM) $−0.3700 · Net margin −135% · Return on equity −21.3% · Return on assets (EBIT) −15.5% · Operating margin −64.1% · Revenue (TTM) $32.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 35% below its 52-week high and 76% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −31%, MXCT screens richer than that median.
Fair Value models
Bear $0.5400Fair Value $0.8200Bull $1.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.16/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−14.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic). Over 10 years: +13.5% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−42.3% (2020) → −137.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside−31% · Below median
Profitability
Return on assets−11% · Bottom 25%
Net margin (TTM)−121% · Bottom 25%
Operating margin (TTM)−64% · Bottom 25%
Growth and dividend
Revenue growth−7% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.74× · Cheaper than median
P/S (TTM)3.92× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 7
HEALTH (low debt)99· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "MaxCyte Inc Fair Value". https://www.fairvalue-calculator.com/stock/MXCT
Frequently asked questions
Is MaxCyte Inc (MXCT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.8200 versus a price of $1.19, about −31% upside (overvalued).
What is the fair value of MXCT?
Our model-based fair value for MaxCyte Inc is $0.8200 (as of Sep 23, 2026), built from audited fundamentals. The current price: $1.19.
What is the quality score of MXCT?
MaxCyte Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MaxCyte Inc (MXCT)?
Our model-based price target is the fair value of $0.8200 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.5400, optimistic scenario $1.02. It is a calculation from audited fundamentals, not an analyst target.
What is the MaxCyte Inc stock forecast for 2026?
Our models put fair value at $0.8200, about −31% upside versus a price of $1.19 (overvalued). Cautious scenario $0.5400, optimistic scenario $1.02. The calculation is refreshed regularly with new filings.
What is the revenue of MaxCyte Inc (MXCT)?
MaxCyte Inc reported trailing-twelve-month revenue of about $32.3M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of MaxCyte Inc (MXCT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MaxCyte Inc it is $0.8200 per share (as of Sep 23, 2026), against a price of $1.19. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is MaxCyte Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, MXCT trades above its calculated fair value: price $1.19, fair value $0.8200, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MXCT?
No. The price is what the market pays today ($1.19); the fair value is what the company's own numbers justify ($0.8200). For MaxCyte Inc the two are $0.3700 per share apart. That gap is exactly why we show both numbers side by side.
How much is MaxCyte Inc worth?
The market values MaxCyte Inc at about $127M (market capitalisation, as of Sep 23, 2026). Per share that is $1.19; our models calculate a fair value of $0.8200 per share.
What do the bullish and bearish scenarios say about MXCT?
Our models span a range for MaxCyte Inc: cautious scenario $0.5400, base $0.8200, optimistic $1.02 per share (as of Sep 23, 2026, price $1.19). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MaxCyte Inc (MXCT)?
Balance-sheet figures for MaxCyte Inc (as of Sep 23, 2026): return on equity −21.3%, debt of 0.03 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is MXCT from its 52-week high?
MaxCyte Inc trades at $1.19, about 35% below its 52-week high of $1.83 and 76% above the low of $0.6760 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8200 is for.
Which stocks are comparable to MaxCyte Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MaxCyte Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $1.19, calculated fair value $0.8200 (−31%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MXCT calculated?
We run MaxCyte Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.8200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. MaxCyte Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MaxCyte Inc (MXCT)?
The closing price on Sep 23, 2026 was $1.19. Our model-based fair value is $0.8200, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MaxCyte Inc right now?
The price sits above even our optimistic bull case ($1.02). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.5400 to $1.02) leaves room in how you read the outcome.
Key figures of MaxCyte Inc
How large is the market capitalisation of MaxCyte Inc (MXCT)?
The market capitalisation of MaxCyte Inc is $127M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MaxCyte Inc (MXCT)?
The price-to-sales ratio of MaxCyte Inc is 4.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MaxCyte Inc (MXCT)?
Earnings per share at MaxCyte Inc are $−0.3700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MaxCyte Inc (MXCT)?
The net margin of MaxCyte Inc is −135% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MaxCyte Inc (MXCT)?
The return on equity (ROE) of MaxCyte Inc is −21.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MaxCyte Inc (MXCT)?
On an EBIT basis the return on assets of MaxCyte Inc is −15.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MaxCyte Inc (MXCT)?
The operating margin of MaxCyte Inc is −64.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MaxCyte Inc (MXCT)?
Revenue at MaxCyte Inc is growing −7.1% versus a year earlier (3y avg −9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MaxCyte Inc (MXCT) generate?
The free cash flow of MaxCyte Inc is −$36.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does MaxCyte Inc (MXCT) hold?
MaxCyte Inc holds more cash than debt, $2.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch MaxCyte Inc in the live analysis
One click puts MaxCyte Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026